Hsbc Holdings PLC Sells 29,002 Shares of REGENXBIO Inc. $RGNX

Hsbc Holdings PLC lowered its position in shares of REGENXBIO Inc. (NASDAQ:RGNX - Free Report) by 34.2% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 55,815 shares of the biotechnology company's stock after selling 29,002 shares during the quarter. Hsbc Holdings PLC owned 0.11% of REGENXBIO worth $390,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in RGNX. Vanguard Group Inc. grew its stake in REGENXBIO by 16.3% in the first quarter. Vanguard Group Inc. now owns 3,472,988 shares of the biotechnology company's stock valued at $24,832,000 after purchasing an additional 487,036 shares in the last quarter. Millennium Management LLC grew its stake in REGENXBIO by 406.3% in the fourth quarter. Millennium Management LLC now owns 1,322,344 shares of the biotechnology company's stock valued at $10,222,000 after purchasing an additional 1,061,187 shares in the last quarter. Balyasny Asset Management L.P. increased its stake in shares of REGENXBIO by 6.0% during the 4th quarter. Balyasny Asset Management L.P. now owns 1,187,102 shares of the biotechnology company's stock worth $9,176,000 after purchasing an additional 66,993 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in shares of REGENXBIO by 1.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,171,422 shares of the biotechnology company's stock worth $9,054,000 after purchasing an additional 21,234 shares during the last quarter. Finally, Two Sigma Investments LP increased its stake in shares of REGENXBIO by 209.2% during the 4th quarter. Two Sigma Investments LP now owns 389,428 shares of the biotechnology company's stock worth $3,010,000 after purchasing an additional 263,495 shares during the last quarter. Institutional investors and hedge funds own 88.08% of the company's stock.

REGENXBIO Stock Performance

Shares of NASDAQ:RGNX traded up $0.29 during midday trading on Friday, reaching $9.71. 609,824 shares of the company's stock were exchanged, compared to its average volume of 643,702. The company's 50 day simple moving average is $8.65 and its two-hundred day simple moving average is $8.18. The firm has a market capitalization of $490.45 million, a PE ratio of -2.82 and a beta of 1.17. REGENXBIO Inc. has a 12 month low of $5.03 and a 12 month high of $13.48.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The biotechnology company reported ($1.38) EPS for the quarter, missing analysts' consensus estimates of ($1.13) by ($0.25). REGENXBIO had a negative return on equity of 66.95% and a negative net margin of 112.70%.The business had revenue of $21.36 million for the quarter, compared to the consensus estimate of $40.87 million. On average, research analysts anticipate that REGENXBIO Inc. will post -4.84 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have recently commented on RGNX shares. Chardan Capital restated a "buy" rating and set a $52.00 price target on shares of REGENXBIO in a research note on Friday, August 8th. HC Wainwright restated a "buy" rating and set a $34.00 price target on shares of REGENXBIO in a research note on Tuesday, August 19th. Royal Bank Of Canada dropped their price target on shares of REGENXBIO from $21.00 to $17.00 and set an "outperform" rating on the stock in a research note on Friday, August 8th. Wall Street Zen lowered shares of REGENXBIO from a "hold" rating to a "strong sell" rating in a research note on Saturday, August 9th. Finally, Barclays cut their target price on shares of REGENXBIO from $50.00 to $37.00 and set an "overweight" rating for the company in a research report on Friday, August 8th. Five equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, REGENXBIO presently has a consensus rating of "Moderate Buy" and an average target price of $28.38.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.